



LONDON CANCER HUB ROUNDTABLE

Sponsored and Hosted by:

MACFARLANES

EVENT DETAILS

- **Topic:** Real Estate Infrastructure for Cancer Innovation
- **Date:** July 14, 2025
- **Time:** From 3:00pm BST (10:00am EDT)
Discussion to run for approximately 2.5 hours
- **Location:** Macfarlanes LLP, 20 Cursitor Street, London EC4A 1LT
- **Followed by:** Dinner at Mcfarlanes Offices (optional)

VIRTUAL MEETING INFO

[Zoom Link](#)

Meeting ID: 952 5652 2465

Password: 252426

AGENDA

3:00 – 3:15 WELCOME AND AGENDA FOR THE DAY

- Nick Barnes, Partner, **Macfarlanes**
Founding Member, **Builds Bio+ London/ UK**
- Alison Wring, Director, **AECOM**
Founding Member, **Builds Bio+ London/ UK**

3:15 – 3:45 INTRODUCTION TO THE LONDON CANCER HUB (Slides)

<https://socius.dev/projects/london-cancer-hub-sutton>

Speaker:

- Daniel May, Director, **Socius**

3:45 – 4:00 WHAT MAKES A REAL ESTATE ECOSYSTEM WORK FOR CANCER RESEARCH?

Moderator/ Speaker:

- Ryan Matenchuk, Chief Executive Officer
Galileo Labs. Founding Member, **Builds Bio+ London/ UK**

Speakers:

- Bill Hunter, President, **Tourmaline Life Sciences**
- Nancy J Kelley, President & CEO, **Nancy J Kelley + Associates**
Founding Member, **Builds Bio+**

4:00 – 4:15 LESSONS FROM TOP PERFORMING US CLUSTERS: BOSTON, NYC, HOUSTON, SEATTLE

Moderator:

- Ryan Matenchuk, Chief Executive Officer, **Galileo Labs**
Founding Member, **Builds Bio+ London/ UK**

Speakers:

- Bill Hunter, President, **Tourmaline Life Sciences**
- Nancy J Kelley, President & CEO, **Nancy J Kelley + Associates**
Founding Member, **Builds Bio+**

4:15 – 4:30 BREAK

4:30 – 4:45 UK BOTTLENECKS: PLANNING, LAND ASSEMBLY, NHS STRATEGY

Moderator:

- Alison Wring, Director, **AECOM**
Founding Member, **Builds Bio+ London/ UK**

Speakers:

- Thomas Holbrow, Business Development Director, **Mace Group**
Founding Member, **Builds Bio+ London/ UK**
- Simon Hephher-Davies, Head of Asset Management-Regent's Place and
Innovation Assets, **British Land**
Founding Member, **Builds Bio+ London/ UK**

4:45 – 5:00 DESIGNING FOR THE SCIENTIST, THE DEVELOPER, AND THE PATIENT

Moderator:

- Tim Burke, Director of Operations/ UK, **Merrick & Co.**
Founding Member, **Builds Bio+ London/ UK**

Speakers:

- Nathan Morgan, Global Sciences Lead, **Gensler**
- Dave Watson, Studio Director, **Gensler**

5:00 – 5:15 PLANNING FOR THE UNKNOWN: FLEXIBILITY, RESILIENCE, AND FUTURE SCIENCE

Moderator:

- Tim Burke, Director of Operations/ UK, **Merrick & Co.**
Founding Member, **Builds Bio+ London/ UK**

Speakers:

- Nathan Morgan, Global Life Sciences Lead, **Gensler**
- Dave Watson, Studio Director, **Gensler**

5:15 – 5:30 RECAP AND NEXT STEPS

5:30 – 6:30 DRINKS

6:30 DINNER

ATTENDEES



TERRY BRANDON MSc MBA MCIQB

Project Director, Project Management, EUR - UK & Ireland

AECOM

Terry initially qualified as a Building Engineering systems and process engineer before studying Architecture and then Law to eventually join AECOM Buildings and Places Group as a Director in the PM team.

Terry is the PM Lead for the Science PM team based in London and is responsible for developing the AECOM Golden Triangle

market strategy. Terry is also working with the AECOM global team coordinating the AECOM Pharma offering.



ALISON WRING

Director Commercial Science/Tech Lead UK/I

AECOM

Alison Wring is a Director of AECOM and is sector lead for Science/Innovation in the UK/Ireland. She focusses on bringing the best possible outcomes for numerous developers looking to create science communities across urban and regional locations. She has authored a number of articles including two cost models on science facilities and is a member of the European Product Council for Life Sciences and Health, contributing to their

research paper on the Future of Real Estate Investment in Life Sciences.



Nicola Carniato MICE MIMechE

Cambridge Studio Director



Experienced Director with a demonstrated history of working in the civil and structural engineering industry. Skilled in Concrete, Steel, Timber and Masonry Structures, Computer-Aided Design (CAD). Strong professional with a Master of Science (M.Sc.) focused in Materials Engineering from Università degli Studi di Udine.



RICHARD SURMA
Head of Estate Development & Capital Programmes



Richard is a senior Estates professional with 25 years leadership in R&D, scientific, highly technical, and regulated development and built environments. He is currently responsible for the development of a capital programme which delivers the Strategic Estates Masterplan; ensures the identification, scoping, senior leadership review and decision making (capital approval/timing/delivery process) and progression of major R&D building projects required. Richard's responsibilities also include the transition of any new capital projects into operational readiness, leading a world class Operational Readiness, transition, and soft landings process. Prior roles and responsibilities include Head of Estates for the BBSRC, providing direction and strategic oversight to a complex and diverse estate covering approximately 1,900 hectares and with a replacement value in excess of £500m at locations across the UK. Richard brings a passion to realising the full potential of science and research infrastructure to deliver leading edge products.



SIMON HEPHER-DAVIES
Head of Asset Management
Regent's Place and Innovation Assets



JUSTIN CRATTY
Chief Scientific Experience Officer



Justin's previous career experience as a scientific researcher provides him with unique knowledge and insight while informing his design work.

In his role as a Sciences Leader, he brings his singular perspective to projects ranging from laboratory strategy and change-management consultancy to the design of scientific

campuses and headquarters. An award-winning designer, Justin is particularly interested in creating the best possible environments to support the work of today's scientists.

He is also the past President of the U.K. Chapter of the American Institute of Architects and is an active member in Gensler's global network, through which he facilitates the exchange of knowledge and best practices throughout the firm.



RYAN MATENCHUK
Chief Executive Officer



Ryan is the Managing Director of Galileo Labs. His business creates and curates lab space for science companies in an urban environment. He is a real estate finance professional with a depth of experience working in the property industry for over 17 years.

He spent the last 8.5 years with Stanhope PLC as part of the new business team that secured, funded and developed Television Centre and White City Place in White City, West London a combined 2.4m sq ft.

Ryan is Co-Chair of the ULI European Life Science & Healthcare Council and a guest lecturer for the LSE MSc Real Estate Economics and Finance course. He holds a BA in Economics, MSc in Real Estate investment and an Executive MBA from Oxford University.



NATHAN MORGAN
Global Sciences Leader & Project Director



Nathan is the Global Sciences Leader and Project Director in Gensler's London office. He leads transformative strategies and innovative teams across the firm, where his knowledge in end-user science clients and speculative development drives industry-leading projects.

His expertise, spanning start up to large pharma, enables him to guide clients through every phase of a project, from campus planning and repositioning to intricate fit outs. Nathan is deeply committed to optimising processes and embedding new ways of working, ensuring that the spaces he designs are not only effective but future ready.



DAVID WATSON

Studio Director

Gensler

As a Studio Director at Gensler London David brings an intuitive and strategic approach to design whilst overseeing projects from concept through to completion. He has over twenty years of experience working on complex architectural and urban design projects across multiple sectors. He combines a passion for history with contemporary design and creative regeneration. For David, it starts with people and history. Whether it be in terms of early-stage brief and design development, working with clients and his design teams or consultation, he uses strong collaborative skills to get the best results.



ANDY CARR

Business Development Manager

ICR The Institute of
Cancer Research

Andy Carr has spent 30 years in economic development, working with hi-tech, hi-growth potential SMEs, commercializing IP, accessing markets and corporates and overcoming growing pains. At the ICR he facilitates relationships between researchers and companies working to defeat cancer, thus building the ICR's commercial revenue to re-invest into further research, accelerating the pace of treatments for patients. He plays a key role in delivering the new London Cancer Hub. A 1m sq ft science campus, dedicated to cancer research.

Before this, as Head of Enterprise at City of London Corporation he delivered a 5-year enterprise strategy, assisting City based tech co's in aerospace and shipping, digital and gaming, film and animation sectors, to access markets, funding, training and suitable accelerator premises.



HENRY FRENCH

Head of Business Marketing and Engagement

ICR The Institute of
Cancer Research

A highly motivated, collaborative networker and communicator with 15 years' experience in business development, communications and marketing at world-class scientific organisations. Extensive experience of building and managing relationships with partners in industry, local government, the

NHS, property development, and venture capital; years of experience in high-pressure media relations, science communication and external engagement roles.

Deep knowledge of oncology research and regulatory landscape, especially in small-molecule drug discovery and development, and the wider policy and funding environment for life-sciences. Degree in Natural Sciences from the University of Cambridge.

Leading role in external engagement for The London Cancer Hub project in Sutton, south London, including for alliance management and marketing campaigns, including for recruitment of companies to life-sciences / oncology incubator the Innovation Gateway. Extensive experience of supporting entrepreneurial scientists.

Professional experience in conservation, dedicated to sustainability with deep interest in natural history.



MITCHEL W. SIMPLER
Partner Emeritus, JB&B



Founding Member & Steering Committee, Builds Bio+

Mitch Simpler joined JB&B, a global consulting engineering firm, in 1977 and currently serves as Partner, after having served as Managing Partner from 2012 - 2018. He has acted as Project Manager and Partner-in-Charge on life/health science institutions, healthcare facilities, high-rise office buildings, museums, residential and mixed-use buildings as well as hotels.

Mr. Simpler's list of notable projects in the life science sector spans the past 40 years, including premier laboratory facilities and research centers in New York City, such as the Jerome L. Greene Science Center at the Columbia University Manhattanville campus; New York Genome Center; Mount Sinai's Hess Center for Science and Medicine; Weill Cornell Medical College's Belfer Research Building; MSK's David H. Koch Center for Cancer Care and Rockefeller Research Laboratories; Cornell University's Biotechnology Building; and NYU Langone Health's Smilow Research Building and Skirball Institute of Biomolecular Medicine. His experience extends around the world to China, with the Innovation Center at Duke Kunshan University in Kunshan and the Rohm & Haas Research Center in Shanghai.

Mr. Simpler is a Fellow of the American Council of Engineering Companies (ACEC) and recently served as the National Chairman for ACEC.



DEAN CADBY
Senior Technical Director, Site/Civil

LANGAN

Mr. Cadby has held design lead roles on significant projects across different sectors for many years. He is a civil and infrastructure engineer with over 30 years of experience and a passion for the built environment. Having worked across various award-winning development projects as a consultant, he is passionate about the places we live and interact with daily. Mr.

Cadby seeks to guide projects to excellence, weaving in design directions to steer a strong sense of place-making and a solid design narrative underpinned by robust engineering principles. Mr. Cadby has acted as design lead on numerous international data center projects. Mr. Cadby's experience in the area brings far-reaching value to each project.



MICHAEL RIORDAN MRICS
Managing Director, United Kingdom

Linesight

As managing director of Linesight's UK operations, Michael oversees a team of highly-skilled professionals, ensuring that the construction consultancy services provided are of the highest standard, that optimum outcomes are delivered for all clients, and that the organization's UK endeavors align with

Linesight's global efforts.

He is Linesight's data center lead, having amassed more than 15 years' experience in the sector, providing strategic advice on project and cost management services to a number of leading owner-occupiers and colocation providers in the UK and throughout Europe.

Michael has had direct responsibility for over 30 data center construction projects globally, delivering over 600MW. His area of expertise includes development management, optional engineering, bespoke procurement solutions, and financial consultancy services.



PRIYA SHAH MEng CEng MChemE
Associate Director - Life Sciences, UK & Europe



Priya is a Chartered Chemical Engineer, who has over 15 years' experience working on high profile projects within a number of highly regulated sectors including pharmaceutical, industrial gases and nuclear. Over the last 8 years, she has managed large-scale projects within the life sciences sector for a number of pharmaceutical clients, and over this time has amassed

extensive knowledge and expertise in the successful delivery of complex pharmaceutical manufacturing and life sciences real estate projects. In her current role, Priya has been involved in developing and growing the life sciences business across the UK and Europe for global construction consultancy firm Linesight and her technical background has enabled her to connect with clients to truly understand the technical complexities of their projects.



NICK ABBEY
Director of Operations



Nick is Director of Operations within Mace's Public Sector and Life Sciences Division which primarily operates across the UK's Golden Triangle. With nearly 30 years in construction, Nick specialises in building collaborative teams with scientists, designers and clients to create world-class environments that enable innovation and excellence. His experience includes major

programmes at Harwell Campus – including the Rosalind Franklin Institute – GSK Ware, and Oxford University's Old Road Campus which is home to leading cancer specialists. His strategic leadership has helped to position Mace as a trusted partner for clients like STFC, AstraZeneca, and top UK universities.



TOM HOLBROW
Business Development Director (Construction)



Tom Holbrow heads up the Business Development function for the Public Sector and Life Science Construction workstreams within Mace Group. Tom has held operational delivery and business development roles during his 35 years within the industry located within the UK and Internationally. Tom is experienced at working on complex projects of all sizes and is

currently focused on expanding Mace's profile with both public and private sector Science and Research clients.



NICK BARNES

Partner

MACFARLANES

Nick has experience of a broad range of commercial real estate work, including development and investment work, joint ventures, commercial lettings (acting for both landlords and tenants) and debt financing.



TIM BURKE

Director of UK Operations



Tim Burke is responsible for Life Sciences practice's operations in the United Kingdom and Europe and provides a regional conduit across the breadth of Merrick's services. He continues to provide strategic advisory services focused on optimizing the development, delivery, and operational performance of high-consequence RDT&E and life sciences infrastructure for industry, academic, and government clients. Prior to Merrick, Tim's experience includes the technical foundation of a professional engineer, gained acumen in strategic planning and business management as a management consultant, and practiced leadership and program guidance as the federal Branch Chief for DHS's Science & Technology Directorate's Laboratory Operations. Tim's career has afforded him a unique breadth of technical and leadership experiences to draw upon when novel solutions are required, from the USPS Anthrax decontamination to biotech start-ups to today's largest research and life science facilities.



PAUL JANSSENSWILLEN

Director UK Growth + Strategy - Life Sciences and Laboratories



Paul is a chartered architect with a proven track record of technical and managerial expertise across 35 years of designing and delivering complex life science facilities across the globe from early research R&D to the manufacturing of dosage forms requiring high levels of biological or chemical containment. An early adopter of prefabricated, standardized component assembly for GSK in the UK and collaborative construction contracts for Pfizer in the UK to deliver flexible facility solutions. Further examples of pioneering innovative solutions to improve the efficiency and effectiveness in facility execution to improve user outcomes has

included leading the transition to a shared asset culture in laboratory design, by deploying 'real-time' occupancy and equipment utilization data acquisition systems for Novartis in Cambridge MA, writing global transformational laboratory guidelines for Amgen and leading the change management of their laboratory relocation in Shanghai, pioneering the introduction of disposable rodent cages in vivarium design to improve safety and data reliability whilst reducing both capital and operational costs for Pfizer in Cambridge, MA and using social network analysis to demonstrate the productivity gains resulting from increases in collaboration and interaction of multi-disciplinary teams for Roche in Germany.



NANCY J KELLEY, JD/MPP

President & CEO, Nancy J Kelley + Associates



NANCY J KELLEY
+ ASSOCIATES



Founding Member & Steering Committee, Builds Bio+

Nancy J Kelley, JD/ MPP, is a nationally recognized executive and serial entrepreneur who has driven key strategic initiatives in science and medicine for over 20 years. Ms. Kelley is a prolific and successful entrepreneur, serving as President and Chief Executive Officer of Nancy J Kelley + Associates, Founder and Chief Executive Officer of Kyttaro Therapeutics, and a Founding Member of Builds Bio+.

She was a member of the Founding Leadership team of the international scientific project Genome Project (GP)-write and the associated Center of Excellence for Engineering Biology, and helped to launch the Biodesign Challenge.

Ms. Kelley was the Founding Executive Director of the New York Genome Center and a lead executive in the development of the East River Science Park (now, Alexandria Life Science Center) in Manhattan.

She has overseen major development projects for clients such as Harvard's McLean Hospital, NIH, Johns Hopkins, and MIT. She has raised over \$230 million to date for the Bioventures she has founded.

Ms. Kelley holds an AS from Manchester Community College, a BA from Yale College, a JD from Harvard Law School and an MPP from Harvard Kennedy School. She has been appointed both a White House Fellow and Truman Scholar.



CLAIRE COCKERTON
Innovation Ecosystems, Populate



MD of Cockerton and Co and advisor to Socius' London Cancer Hub, Claire Cockerton is an expert in real estate innovation, place-making and community building, having created multiple innovation centres, such as Plexal, Level39, and Lorca. To activate these developments, Claire designs and delivers business services, programmes and events which serve to support start-up and corporate collaboration, and the creation of new technology clusters.

Claire advises on real estate innovation projects such as; the Schwartz Reisman Innovation Centre (Life Sciences centre at University of Toronto), the BioQuarter (Life Sciences Innovation District in Edinburgh), Nexus (Deep Tech innovation centre in Leeds) and Cognicity (a Prop-tech and Smart Cities accelerator in Canary Wharf). Claire also founded the UK's Fintech trade body, Innovate Finance collaborating with the UK Government, the regulator, City of London Corporation and fintech founders – all committed to delivering a more customer-centric, digital and transparent financial services industry.


Claire is an influential change-maker, Member of the City of London Guild of Entrepreneurs, Member of the London Mayor's Tech Ambassadors group, and named the 4th most influential woman in UK tech by Computer Weekly.



FAAIZA LALJI
Director of Planning and Development
Precis Advisory

Faaiza is the Director of Planning and Development at Precis Advisory where she oversees a new residential-led mixed use build to rent portfolio in Outer London representing 2,500 homes and 1 million sqft of workspace and storage. She also leads on the company's life sciences and sustainability-focused projects, the flagship of which is located in the heart of the King's Cross Knowledge Quarter and Innovation District. Faaiza sits on the Harvard Alumni Real Estate Board, the Urban Land Institute's European Life Sciences and UK Residential Councils, the British Property Foundation's Residential Build to Rent Committee, and the Young Camden Foundation Trustee Board.

NLA Expert Panel member for the Innovation Districts programme #NLAINnovation



DANIEL MAY

Director

SOCIUS

Daniel is a director at Socius and boasts over 20 years of industry experience. He has been involved in all phases of development, specialising in enhancing value creation through his expertise in design, planning, engineering, financing, and construction.

Daniel is currently leading the development team for the London Cancer Hub, aiming to establish a sustainable district dedicated to excellence in cancer research. This project focuses on creating a new ecosystem of labs, R&D, and commercial facilities, complemented by essential amenities and accommodations designed to attract top global researchers and expedite the development of pioneering cancer treatments.

Within Socius, Daniel oversees the portfolio of projects, ensuring the integrity of the project vision and placemaking agenda. He also leads the company's 'People & Performance' strategy, demonstrating his commitment to fostering both organisational and employee growth.



Gavin Henderson, MA (CANTAB), Dip Arch, RIBA

Principal Director

**STANTON
WILLIAMS**

Gavin Henderson is a Principal Director at Stanton Williams, an internationally recognised architecture practice known for thoughtful approaches to sensitive sites and complex, ambitious projects.

Gavin's expertise spans diverse scales and building types, with a particular focus on innovative educational, science and research spaces within complex urban contexts. He has an especial interest in the interrelationship of these disciplines and urban life, and the design of environments that foster knowledge exchange and collaboration and which prioritise human experience.

Gavin has led a number of the practice's high-profile projects including the Stirling Prize winning Sainsbury Laboratory, University of Cambridge, the Zayed Centre for Research at Great Ormond Street Hospital, and UCL Marshgate, a state of the art 35,000m2 interdisciplinary research and teaching building within London's Olympic Park. He is currently leading the design of a new Cancer Centre for the Royal Marsden Hospital, Chelsea and the new Fleming Centre for Imperial College Healthcare Trust.

Beyond practice, he contributes to architectural discourse through lecturing, critiquing, and serving on committees including the Society of Antiquaries of London, NLA Expert Panels, as well as chairing the RIBA Regional Awards.



LEWIS BUTLER
Director of Strategy
The ROYAL MARSDEN
NHS Foundation Trust

Lewis trained as a chartered accountant with PWC before working for over three years at Monitor in the Foundation Trust Assessment Team.

Lewis joined The Royal Marsden eleven years ago and up to 2021 worked in several senior roles in the finance team where he led the establishment of our commercial function and supported the setup of the Trust's digital transformation projects.

While in finance roles he previously worked on a wide range of other projects including the NIHR Biomedical Research Centre application, the diagnostic imaging strategy and the collaboration with Bupa Cromwell to support the Surgical Hub during COVID.

Lewis took on the role of Director of Strategy in March 2021 and responsibilities include strategy development and application, management of the Transformation function and responsibility for driving new commercial partnerships and offerings. Key projects Lewis has led in this role include: Coordinating the Trust's new 5 year clinical strategy, developing the long-term Sutton site strategy; initial scoping of the planned Chelsea major site redevelopment; reshaping the Transformation Programme post EPIC implementation and several Genomics developments including the NHS's first at scale ctDNA service.



WILLIAM "BILL" D. HUNTER
Senior Vice President, Tourmaline Life Sciences

Tourmaline

Hunter boasts a career spanning more than two decades in the life sciences sector, having completed more than \$10 billion in acquisitions, including 12 million square feet of leasing and over five million square feet of strategic campus re-positioning projects for major research-driven institutions nationwide. His expertise focuses upon the adaptive re-use and re-purposing of complex infrastructure assets geared towards addressing the comprehensive and nuanced needs of firms throughout the life sciences ecosystem.

Hunter was a pre-IPO founding executive at BioMed Realty Trust (now Blackstone) and Wexford Science + Technology (acquired by BMR and subsequently sold to Ventas). Prior to joining Tourmaline, Hunter co-founded Thor Life Sciences & Lightstone Life Sciences, both family office-backed life sciences platforms based in NYC.



GERT ATTARD

Professor Gerhardt Attard MD FRCP PhD

Director, University College London Cancer Institute

Team Leader, Treatment Resistance Lab, University College London

Medical Oncology consultant, University College London Hospital



Prof Attard is a John Black Charitable Foundation Endowed Chair in Urological Cancer Research at University College London. He is Team Leader of the Treatment Resistance Group at the UCL

Cancer Institute and a medical oncology consultant treating advanced prostate cancer at UCL Hospital. He graduated with a degree in Medicine from the University of Malta in June 1999 and obtained a PhD in Medicine from the University of London (Institute of Cancer Research) in 2010. He was awarded a Cancer Research UK clinician scientist fellowship in 2013 and a senior investigator award in 2017. His main research interests are dissecting treatment resistance, currently with a focus on plasma DNA analysis, in order to inform on the development of novel therapeutics and biomarkers for castration resistant prostate cancer (CRPC), and improving treatments for patients presenting with metastatic prostate cancer. He is an experienced clinical trialist and a co-author of more than 250 peer-reviewed manuscripts, including several important papers on advanced prostate cancer (H index, 77). Most notably his work led to the development of abiraterone acetate for prostate cancer and recently its approval for high-risk localized disease. Prof Attard's awards over the years include the ASCO Foundation Annual Merit Award in 2007, Prostate Cancer Foundation Young Investigator Award in 2008, the AACR-GlaxoSmithKline Outstanding Clinical Scholar Award in 2009, the Medical Research Society/Academy of Medical Sciences Sue McCarthy Prize in 2010 and the McElwain award in 2010. He received the Cancer Research UK Future Leader Award in 2017 and the Agilent Future Thought Leaders award in 2022. Prof Attard sits on a number of advisory boards and the editorial board of Annals of Oncology.



DR. JANE KINGHORN
Director, Translational Research Office



Jane has extensive experience in developing therapies (of differing modalities) to clinical benefit gained from 20+ years working in large pharma and academia. Her experience has spanned the drug discovery pathway, leading projects through target validation, lead optimisation, candidate selection through to the clinic and regulatory affairs.

Jane as Director of the Translational Research office is responsible for a team of highly experienced applied scientists tasked with establishing the organisational culture, capability and processes necessary to deliver the UCL and BRCs mission of "Accelerating translation for health and wealth".



EMMA MORRIS
BA MA MB BChir PhD FRCP FRCPATH FMedSci




Dean, Faculty of Medical Sciences, UCL.

Professor of Clinical Cell and Gene Therapy, UCL Institute of Immunity & Transplantation. Consultant Haematologist (Haematopoietic Stem Cell Transplantation and Gene Therapy) at UCLH & Royal Free NHS FTs.

Professor Morris is a clinician scientist, clinically trained in haematology and allogeneic HSCT. Her current clinical practice is in HSCT, cellular and gene therapies for haematological malignancies and inherited immune deficiencies. She has developed and led the national allogeneic HSCT centre for adults with primary immune deficiencies (PID) at the UCL Centre for Immunodeficiency and co-ordinates an international MDT.

Her basic science research focus is on T cell immunology, inherited immunodeficiencies, gene therapy and gene editing. She leads a group interested in altering both the specificity and the function of gene-modified immune cells and stem cells. More recent research is focused on developing gene editing techniques as treatments for patients with PID. This research spans the entire translational pathway from animal models to in vitro experimental immunology to Phase I 'first time in man' clinical studies.

Alongside her role as Dean, Faculty Medical Sciences, Emma is the Director of the NIHR UCLH/UCL Biomedical Research Centre Inflammation, Immunity and Immunotherapeutics (III) Theme. She is patron of the charity Haematology Cancer Care (HCC) which raises money for UCLH. Professor Morris is a scientific founder of UCL Spin-out, Quell Therapeutics Ltd, which is developing gene-engineered regulatory T cells for transplant tolerance and autoimmune indications. She was elected to the Academy of Medical Sciences in 2020.



DR CARMEL REILLY PhD MBA
Head of Business & Innovation Group
Translational Research Office



Dr. Carmel Reilly PhD MBA is a life science CEO, founder and venture builder of drug and clinical development companies. Carmel joins as the Head of Business & Innovation Group to drive and support strategic business partnerships in health with the UCL Translational Research Office and partner organisations. Carmel brings CEO experience from leading and founding a drug therapeutics and clinical development company, and brings prior experience of developing translational medicine projects in diverse areas into partnerable programmes and spin-outs.



PAUL REEVES
Managing Director



Paul Reeves has over 20 years' experience in the diagnostics, medical devices and pharmaceutical industry. Paul has a track record of taking products to market with multiple CE-IVD and FDA approvals. He was previously Head of R&D at veterinary pharmaceuticals company VetPlus and led development of a portfolio of products generating £70m sales per annum. Earlier, Paul was Director of R&D at Arcis Biotechnology delivering innovative and disruptive solutions in the sample preparation and biodefense industry, and also part of the team at QIAGEN that led the successful PMA approval of the Therascreen® IVD platform and assay technology.

Paul holds a PhD in Molecular Biology from the University of Liverpool and an MBA from Cranfield University.

[illegible]

[illegible]

[illegible]